METASTATIC HER2-POSITIVE BREAST CANCER
Clinical trials for METASTATIC HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to outsmart resistant breast cancer
Disease control Recruiting nowThis phase 2 trial is testing whether adding evorpacept to standard trastuzumab and chemotherapy can shrink tumors in people with metastatic HER2-positive breast cancer who have already tried the drug Enhertu. About 120 participants will receive the combination intravenously. The…
Matched conditions: METASTATIC HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for Hard-to-Treat breast cancer: zanidatamab trial launches
Disease control Recruiting nowThis phase 3 trial is testing whether a new drug called zanidatamab, given with chemotherapy, works better than the current standard treatment (trastuzumab plus chemo) for people with metastatic HER2-positive breast cancer that has worsened after prior therapy. About 550 adults w…
Matched conditions: METASTATIC HER2-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Can heart drugs shield cancer patients from chemo damage?
Knowledge-focused Recruiting nowThis study looks at heart problems in people with HER2+ breast cancer that has spread. All participants are taking trastuzumab-based treatment. The main goal is to see how often heart issues occur, especially in those also taking beta blockers or similar heart medications. A smal…
Matched conditions: METASTATIC HER2-POSITIVE BREAST CANCER
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC